Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Censoring Survival Data

Censoring Survival Data

Survival analysis is a statistical method used to analyze time-to-event data, often employed in fields such as medicine, engineering, and social sciences. One of the key challenges in survival analysis is dealing with incomplete data, a phenomenon known as "censoring." Censoring occurs when the event of interest (such as death, relapse, or system failure) has not occurred for some individuals by the end of the study period or is otherwise unobservable, and it might have many different...

Comparing the Survival Analysis of Two or More Groups

Comparing the Survival Analysis of Two or More Groups

Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...

Assumptions of Survival Analysis

Assumptions of Survival Analysis

Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.

Randomized Experiments

Randomized Experiments

The randomization process involves assigning study participants randomly to experimental or control groups based on their probability of being equally assigned. Randomization is meant to eliminate selection bias and balance known and unknown confounding factors so that the control group is similar to the treatment group as much as possible. A computer program and a random number generator can be used to assign participants to groups in a way that minimizes bias.
Simple randomization
Simple...

Blinding

Blinding

Blinding is a commonly used method of not telling participants which treatment a subject is receiving. Blinding is a critical part of a randomized control trial or RCT. It reduces the bias that affects the results. In an RCT, blinding is used in the form of a placebo. A placebo effect occurs when untreated subjects falsely believe they have received the treatment and report improved symptoms. A placebo or a dummy treatment is administered to subjects to negate the bias caused by such an effect.

Truncation in Survival Analysis

Truncation in Survival Analysis

Truncation in survival analysis refers to the exclusion of individuals or events from the dataset based on specific criteria related to the time of the event. This exclusion can happen in two primary forms: left truncation and right truncation.
Left truncation occurs when individuals who experienced the event of interest before a certain time are not included in the study. This is often due to a "delayed entry" into the study where only those who survive until a certain entry point are...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Statistical analysis of disease onset during lifespan with left truncation.

Biometrics·2026

Same author

Phase 2A Proof-of-Concept Double-Blind, Randomized, Placebo-Controlled Trial of Nicotinamide in Early Alzheimer Disease.

Neurology·2024

Same author

Censoring-robust time-dependent receiver operating characteristic curve estimators.

Statistics in medicine·2021

See all related articles

Search research articles

Related Experiment Video

Updated: Jan 8, 2026

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

Censoring-robust estimation in fixed sample time-to-event clinical trials with adaptive randomization.

Navneet R Hakhu¹, Daniel L Gillen²

¹Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA 02115, United States.

|December 19, 2025

Summary

Adaptive randomization in clinical trials can bias results for time-to-event data. A new robust estimator corrects for altered censoring patterns, improving treatment efficacy estimates.

Keywords:

adaptive randomization censoring-robust estimation clinical trial model misspecification time-to-event endpoint time-varying effects

More Related Videos

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure

Published on: June 10, 2025

An R-Based Landscape Validation of a Competing Risk Model

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

Related Experiment Videos

Last Updated: Jan 8, 2026

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure

Published on: June 10, 2025

An R-Based Landscape Validation of a Competing Risk Model

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

Area of Science:

Clinical Trials Methodology
Biostatistics
Survival Analysis

Background:

Adaptive randomization dynamically adjusts treatment allocation probabilities during clinical trials.
Its impact on estimating treatment efficacy in time-to-event trials with time-varying effects is not fully understood.
Existing methods may be unreliable when treatment effects change over time.

Purpose of the Study:

To investigate the effects of adaptive randomization on estimating marginal hazard ratios in time-to-event trials.
To develop and validate a robust statistical method to address potential biases introduced by adaptive randomization.
To apply the proposed method to real-world clinical trial data.

Main Methods:

Analytical derivation showing adaptive randomization alters censoring patterns.
Monte Carlo simulations to assess bias in the Cox proportional hazards estimator.
Development of a censoring-robust estimator using reweighted partial likelihood scores.
Derivation of asymptotic properties and finite sample evaluation of the proposed estimator.

Main Results:

Adaptive randomization demonstrably alters censoring patterns in time-to-event trials.
The standard Cox proportional hazards estimator can produce biased results under adaptive randomization.
The proposed censoring-robust estimator effectively corrects for these biases.
The method's performance was validated through simulations and application to a real AIDS clinical trial.

Conclusions:

Adaptive randomization requires careful consideration in time-to-event trial analysis due to potential bias.
The proposed robust estimator provides a reliable method for estimating treatment efficacy.
This approach enhances the accuracy of survival analysis in adaptive clinical trials.